NOVABRIDGE BIOSCIENCES (NBP) Stock Price, Forecast & Analysis
USA - NASDAQ:NBP - US44975P1030 - ADR
NBP Key Statistics, Chart & Performance
The current stock price of NBP is 4 USD.
NBP Latest News, Press Relases and Analysis
NBP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About NBP
Company Profile
I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company is headquartered in Rockville, Maryland and currently employs 32 full-time employees. The company went IPO on 2020-01-17. The firm is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.
Company Info
NOVABRIDGE BIOSCIENCES
Suite 400, 2440 Research Blvd
Rockville MARYLAND US
Employees: 32
Phone: 13016702800
NOVABRIDGE BIOSCIENCES / NBP FAQ
Can you describe the business of NOVABRIDGE BIOSCIENCES?
I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company is headquartered in Rockville, Maryland and currently employs 32 full-time employees. The company went IPO on 2020-01-17. The firm is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.
Can you provide the latest stock price for NOVABRIDGE BIOSCIENCES?
The current stock price of NBP is 4 USD. The price decreased by -4.53% in the last trading session.
Does NOVABRIDGE BIOSCIENCES pay dividends?
NBP does not pay a dividend.
What is the ChartMill rating of NOVABRIDGE BIOSCIENCES stock?
NBP has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of NBP stock?
NOVABRIDGE BIOSCIENCES (NBP) operates in the Health Care sector and the Biotechnology industry.
NBP Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to NBP.
NBP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NBP. NBP has a great financial health rating, but its profitability evaluates not so good.
NBP Financial Highlights
Over the last trailing twelve months NBP reported a non-GAAP Earnings per Share(EPS) of -0.43. The EPS increased by 89.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.22% | ||
| ROE | -19.14% | ||
| Debt/Equity | 0 |